Luca Triggiani1, Rosario Mazzola2, Stefano Maria Magrini1, Gianluca Ingrosso3, Paolo Borghetti1, Fabio Trippa4, Andrea Lancia3, Beatrice Detti5, Giulio Francolini5, Fabio Matrone6, Roberto Bortolus6, Giuseppe Fanetti6, Ernesto Maranzano4, Francesco Pasqualetti7, Fabiola Paiar7, Marco Lorenzo Bonù1, Alessandro Magli8, Alessio Bruni9, Ercole Mazzeo9, Ciro Franzese10, Marta Scorsetti10,11, Filippo Alongi1,12, Barbara Alicja Jereczek-Fossa13,14, Piet Ost15, Michela Buglione1. 1. Radiation Oncology Department, University and Spedali Civili Hospital, Brescia, Italy. 2. Radiation Oncology Department, IRCCS, Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy. rosariomazzola@hotmail.it. 3. Department of Radiation Oncology, Policlinico Tor Vergata, University of Rome, Rome, Italy. 4. Radiation Oncology Centre, "S. Maria" Hospital, Terni, Italy. 5. Department of Radiation Oncology, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. 6. Department of Radiation Oncology, Centro di Riferimento Oncologico di Aviano CRO-IRCCS, Aviano, PN, Italy. 7. Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy. 8. Department of Radiation Oncology, University Hospital of Udine, ASUIUD, Udine, Italy. 9. Radiotherapy Unit, Oncology and Hematology Department, University Hospital of Modena, Modena, Italy. 10. IRCCS, Radiotherapy and Radiosurgery Department, Humanitas University Hospital, Milan-Rozzano, Italy. 11. Department of Biomedical Sciences, Humanitas University, Milan-Rozzano, Italy. 12. Radiation Oncology Department, IRCCS, Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy. 13. Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy. 14. Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy. 15. Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
Abstract
PURPOSE: Herein, we report the clinical outcomes of a multicenter study evaluating the role of SBRT in a cohort of patients affected by oligoprogressive castration-resistant prostate cancer (CRPC). MATERIALS AND METHODS: This is a retrospective multicenter observational study including eleven centers. Inclusion criteria of the current study were: (a) Karnofsky performance status > 80, (b) histologically proven diagnosis of PC, (c) 1-5 oligoprogressive metastases, defined as progressive disease at bone or nodes levels (detected by means of choline PET/CT or CT plus bone scan) during ADT, (d) serum testosterone level under 50 ng/ml during ADT, (e) controlled primary tumor, (f) patients treated with SBRT with a dose of at least 5 Gy per fraction to a biologically effective dose (BED) of at least 80 Gy using an alpha-to-beta ratio of 3 Gy, (g) at least 6 months of follow-up post-SBRT. RESULTS: Eighty-six patients for a total of 117 lesions were treated with SBRT. The median follow-up was 30.7 months (range 4-91 months). The median new metastasis-free survival after SBRT was 12.3 months (95% CI 5.5-19.1 months). One- and two-year distant progression-free survival was 52.3% and 33.7%, respectively. Twenty-six out of 86 patients underwent a second course of SBRT due to further oligoprogressive disease: This resulted in a median systemic treatment-free survival of 21.8 months (95% CI 17.8-25.8 months). One-year systemic treatment-free survival was 72.1%. CONCLUSION: SBRT appears to be a promising approach in oligoprogressive castration-resistant prostate cancer. Further investigations are warranted.
PURPOSE: Herein, we report the clinical outcomes of a multicenter study evaluating the role of SBRT in a cohort of patients affected by oligoprogressive castration-resistant prostate cancer (CRPC). MATERIALS AND METHODS: This is a retrospective multicenter observational study including eleven centers. Inclusion criteria of the current study were: (a) Karnofsky performance status > 80, (b) histologically proven diagnosis of PC, (c) 1-5 oligoprogressive metastases, defined as progressive disease at bone or nodes levels (detected by means of choline PET/CT or CT plus bone scan) during ADT, (d) serum testosterone level under 50 ng/ml during ADT, (e) controlled primary tumor, (f) patients treated with SBRT with a dose of at least 5 Gy per fraction to a biologically effective dose (BED) of at least 80 Gy using an alpha-to-beta ratio of 3 Gy, (g) at least 6 months of follow-up post-SBRT. RESULTS: Eighty-six patients for a total of 117 lesions were treated with SBRT. The median follow-up was 30.7 months (range 4-91 months). The median new metastasis-free survival after SBRT was 12.3 months (95% CI 5.5-19.1 months). One- and two-year distant progression-free survival was 52.3% and 33.7%, respectively. Twenty-six out of 86 patients underwent a second course of SBRT due to further oligoprogressive disease: This resulted in a median systemic treatment-free survival of 21.8 months (95% CI 17.8-25.8 months). One-year systemic treatment-free survival was 72.1%. CONCLUSION: SBRT appears to be a promising approach in oligoprogressive castration-resistant prostate cancer. Further investigations are warranted.
Authors: Philip Cornford; Joaquim Bellmunt; Michel Bolla; Erik Briers; Maria De Santis; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Thomas Wiegel; Nicolas Mottet Journal: Eur Urol Date: 2016-08-31 Impact factor: 20.096
Authors: Charles J Ryan; Matthew R Smith; Karim Fizazi; Fred Saad; Peter F A Mulders; Cora N Sternberg; Kurt Miller; Christopher J Logothetis; Neal D Shore; Eric J Small; Joan Carles; Thomas W Flaig; Mary-Ellen Taplin; Celestia S Higano; Paul de Souza; Johann S de Bono; Thomas W Griffin; Peter De Porre; Margaret K Yu; Youn C Park; Jinhui Li; Thian Kheoh; Vahid Naini; Arturo Molina; Dana E Rathkopf Journal: Lancet Oncol Date: 2015-01-16 Impact factor: 41.316
Authors: Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf Journal: N Engl J Med Date: 2012-12-10 Impact factor: 91.245
Authors: Piet Ost; Alberto Bossi; Karel Decaestecker; Gert De Meerleer; Gianluca Giannarini; R Jeffrey Karnes; Mack Roach; Alberto Briganti Journal: Eur Urol Date: 2014-09-17 Impact factor: 20.096
Authors: Ciro Franzese; Matteo Perrino; Marco Antonio Marzo; Marco Badalamenti; Davide Baldaccini; Giuseppe D'Agostino; Beatrice Marini; Fabio De Vincenzo; Paolo Andrea Zucali; Marta Scorsetti Journal: Clin Exp Metastasis Date: 2022-02-21 Impact factor: 5.150
Authors: Matthew P Deek; Kekoa Taparra; Ryan Phillips; Pedro Isaacsson Velho; Robert W Gao; Curtiland Deville; Daniel Y Song; Stephen Greco; Michael Carducci; Mario Eisenberger; Theodore L DeWeese; Samuel Denmeade; Kenneth Pienta; Channing J Paller; Emmanuel S Antonarakis; Kenneth R Olivier; Sean S Park; Phuoc T Tran; Bradley J Stish Journal: Eur Urol Oncol Date: 2020-06-11